ISSN 2305-3127 (Print)   
ISSN 2664-3790 (Online)

 

TAVI: past, present and future. On the 20th anniversary of the world’s first endovascular aortic valve implant

M.V. Stan, A.V. Khokhlov, O. V. Zelenchuk, B.M. Todurov, N.V. Ponych, M.B. Todurov, Kh.M. Monastyrska, M.Ya. Slyubyk, Ya.A. Antoniuk

References

  1. ACC Annual Scientific Session, ACC22. CoreValve US Pivotal and SURTAVI Trials Show Rate of SVD Lower With TAVR Than With SAVR. Apr 04, 2022.
  2. Ali N, Faour A, Rawlins J, et al. «Valve for Life»: tackling the deficit in transcatheter treatment of heart valve disease in the UK. Open Heart. 2021;8:e001547. doi:10.1136/ openhrt-2020-001547.
  3. Amat-Santos IJ, Rodés-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;59:178. doi:10.1016/j.jacc.2011.09.061.
  4. Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, et al. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017;70:42–55. doi:10.1016/j.jacc.2017.04.053.
  5. Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:673–84. doi:10.1016/j.jacc.2016.05.065.
  6. Baumgartner H, Falk V, Bax JJ, De Bonis M, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91. doi:10.5603/KP.2018.0013
  7. Bourguignon T, Bouquiaux-Stablo A-L, Candolfi P, Mirza A, et al. Very long-term outcomes of the carpentier-edwards perimount valve in aortic position. Ann Thorac Surg. 2015;99:831–7. doi:10.1016/j.athoracsur.2014.09.030.
  8. Brouwer J MD, Nijenhuis VJ MD, Delewi R MD, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;383:1447–57. DOI:10.1056/NEJMoa2017815.
  9. Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017;69:325–44. doi:10.1016/j.jacc.2016.10.066.
  10. Carroll JD, Mack MJ, Vemulapalli S, Herrmann HC, et al. STS-ACC TVT Registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:2492–516. doi:10.1016/j.jacc.2020.09.595.
  11. Carroll JD, Vemulapalli S, Dai D, Matsouaka R, et al. Procedural experience for transcatheter aortic valve replacement and relation to outcomes. J Am Coll Cardiol. 2017;70:29. doi:10.1016/j.jacc.2017.04.056.
  12. Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–92. doi:10.1016/S0140-6736(17)30757-2.
  13. Chamandi C, Puri R, Rodriguez-Gabella T, Rodés-Cabau J. Latest-generation transcatheter aortic valve replacement devices and procedures. Can J Cardiol. 2017;33:1082–90.  doi:10.1016/j.cjca.2017.03.012.
  14. Chambers JB, Garbi M, Nieman K, et al. Appropriateness criteria for the use of cardiovascular imaging in heart valve disease in adults: a European Association of Cardiovascular Imaging report of literature review and current practice. Eur Heart J Cardiovasc Imaging. 2017;18:489–98. doi:10.1093/ehjci/jew309.
  15. Christos Eftychiou, Nicolaos Eteocleous, Ioannis Zittis, et al. Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality. Hellenic J Cardiol. 2021;62(1):57–64. doi:10.1016/j.hjc.2020.09.011.
  16. David TE, Armstrong S, Maganti M. Hancock II bioprosthesis for aortic valve replacement: the gold standard of bioprosthetic valves durability? Ann Thorac Surg. 2010;90:775–81. doi:10.1016/j.athoracsur.2010.05.034.
  17. de Brito FS, Carvalho LA, Sarmento-Leite R, et al. Brazilian TAVI Registry investigators. Outcomes and predictors of mortality after transcatheter aortic valve implantation: results of the Brazilian registry. Catheter Cardiovasc Interv. 2015;85:E153–E162. doi:10.1002/ccd.25778.
  18. Deharo P, Bisson A, Herbert J, et al. Transcatheter valve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J Am Coll Cardiol. 2020;76(5):489–99. https://doi.org/10.1016/j.jacc.2020.06.010.
  19. Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons / American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2016;9:2189–99. doi.org/10.1016/j.jcin.2016.07.026.
  20. Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis: the REPRISE III randomized clinical trial. JAMA. 2018;319:27–37. doi:10.1001/jama.2017.19132.
  21. Fröhlich GM, Baxter PD, Malkin CJ, et al. Comparative survival after transapical, direct aortic, and subclavian transcatheter aortic valve implantation (data from the UK TAVI Registry). Am J Cardiol. 2015;116:1555–9. doi:10.1016/j.amjcard.2015.08.035.
  22. Fuchs A, De Backer O, Brooks M, et al. Subclinical leaflet thickening and stent frame geometry in self-expanding transcatheter heart valves. EuroIntervention. 2017;13:e1067–e1075. DOI:10.4244/EIJ-D-17-00373.
  23. Gozdek M, Raffa GM, Suwalski P, et al. SIRIO-TAVI group. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2018;53:495–504. doi:10.1093/ejcts/ezx347.
  24. Greenbaum AB, Neill WW, Paone G, et al. Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients. J Am Coll Cardiol. 2014;63:2795. doi:10.1016/j.jacc.
  25. Hamm CW, Arsalan M, Mack MJ. The future of transcatheter aortic valve implantation. Eur Heart J. 2016;37:803–10. doi:10.1093/eurheartj/ehv574.
  26. Husser O, Kim W-K, Pellegrini C, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv. 2017;10:2078. doi:10.1016/j.jcin.2017.06.026.
  27. Kapadia SR, Krishnaswamy A. Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement: Connecting Intuition and Proof. J Am Coll Cardiol Intv. 2021;14(2);169–71. DOI:10.1016/j.jcin.2020.11.025.
  28. Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75:1882–93. doi:10.1016/j.jacc.2020.02.051.
  29. Latib A, Naim C, De Bonis M, et al. TAVR-associated prosthetic valve infective endocarditis: results of a large, multicenter registry. J Am Coll Cardiol. 2014;64:2176–8. doi: 10.1016/j.jacc.2014.09.021.
  30. Ledwoch J, Franke J, Gerckens U, et al. German Transcatheter Aortic Valve Interventions Registry Investigators. Incidence and predictors of permanent pacemaker implantation following transcatheter aortic valve implantation: analysis from the German transcatheter aortic valve interventions registry. Catheter Cardiovasc Interv. 2013;82:E569–E577. doi:10.1002/ccd.24915.
  31. Leon MB, Mack MJ, Hahn RT, et al, PARTNER 3 Investigators. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77:1149–61. doi.org/10.1016/j.jacc.2020.12.052.
  32. Leon MB, Smith CR, Mack M, et al., PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607. doi:10.1056/NEJMoa1008232.
  33. Leon MB, Smith CR, Mack MJ, et al., PARTNER 2 Investiga­tors. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20. doi: 10.1056/NEJMoa1514616.
  34. Liao Y-B, Zhao Z-G, Wei X, et al. Transcatheter aortic valve implantation with the self-expandable venus A-Valve and CoreValve devices: preliminary experiences in China. Catheter Cardiovasc Interv. 2017;89:528–33. doi:10.1002/ccd.26912.
  35. Ludman P. Personal communication: analysis of in-hospital mortality in UK TAVI dataset. 2018. DOI:10.1136/heartjnl-2018-313510.
  36. Ludman P. UK TAVI audit slide set 2007–2016. https://www.bcis.org.uk/education/bcis-audit-report-tavi-2016 (20 April 2018).
  37. Iung B, Cachier A, Baron G, Messika-Zeitoun D, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26:2714–20. doi: 10.1093/eurheartj/ehi471.
  38. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019; 380:1695–705. doi: 10.1056/NEJMoa1814052.
  39. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24. DOI: 10.1056/NEJMoa1509233.
  40. Makkar RR, Thourani VH, Mack MJ, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382:799–809. DOI:10.1056/NEJMoa1910555.
  41. Mylotte D, Lefevre T, Søndergaard L, Piazza N, et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol. 2014;64:2330. doi:10.1016/j.jacc.2014.09.039.
  42. Nazif TM, Dizon José M, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60–9. doi:10.1016/j.jcin.2014.07.022.
  43. Oguri A, Yamamoto M, Mouillet G, et al. Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia. Circ Cardiovasc Interv. 2014;7:602. doi:10.1161/CIRCINTERVENTIONS.113.000403.
  44. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin III JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt III TM, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;143:e35–e71. doi.org/10.1161/CIR.0000000000000932.
  45. Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–15. DOI: 10.1056/NEJMoa1816885.
  46. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–15. doi:10.1056/NEJMoa1816885.
  47. Reardon MJ, Van Mieghem NM, Popma JJ, SURTAVI Investigators, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31. doi:10.1056/NEJMoa1700456.
  48. Regueiro A, Linke A, Latib A, Ihlemann N, et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA. 2016;316:1083–92. doi:10.1001/jama.2016.12347.
  49. Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–65. doi:10.1016/j.jcin.2017.04.014.
  50. Sharma SK, MD, FACC, FSCAI; Rao RS, et al. First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study. Eurointervention. 2020;16(5):421–9. doi:10.4244/EIJ-D-19-00413.
  51. Shen Y, Zhang H MM, Zhang L MD, et al. Transcatheter aortic valve replacement with balloon-expandable valve. Herz. 2018;43(8):746–51. doi: 10.1007/s00059-017-4622-x.
  52. Shimura T, Yamamoto M, Kano S, et al. Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation. 2017;135:2013. doi:10.1161/CIRCULATIONAHA.116.025630.
  53. Siontis GC, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129–40. doi: 10.1016/j.jacc.2014.04.033.
  54. Siontis GCM, Overtchouk P, Cahill TJ, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143–53. doi:10.1093/eurheartj/ehz275.
  55. Siontis GC, Praz F, Pilgrim T, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J. 2016;37:3503–12. doi:10.1093/eurheartj/ehw225.
  56. Tam DY, Vo TX, Wijeysundera HC. Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018;92:1404–11. doi:10.1002/ccd.27686.
  57. Thourani VH, Kodali S, Makkar RR, Herrmann HC, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218–25. DOI:https://doi.org/10.1016/S0140-6736(16)30073-3.
  58. Thyregod HG, Steinbruchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65:2184–94. doi:10.1016/j.jacc.2015.03.014.
  59. Thyregod HGH, Ihlemann N, Jorgensen TH, et al. Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation. 2019;139:2714–23. doi:10.1161/CIRCULATIONAHA.118.036606.
  60. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;43(7):561–32.  https://doi.org/10.1093/eurheartj/ehab395. 
  61. Walther T, Hamm CW, Schuler G, Berkowitsch A, et al. Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry. J Am Coll Cardiol. 2015;65:2173–80. doi:10.1016/j.jacc.2015.03.034.
  62. Yoon S-H, Bleiziffer S, De Backer O, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol. 2017;69:2579–89.
  63. Yoon S-H, Lefèvre T, Ahn J-M, et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol. 2016;68:1195–205. doi:10.1016/j.jacc.2016.06.041.
[PDF] [Contents]  

 

Crossref Member Badge

© "Cardiac Surgery and Interventional Cardiology" Ukrainian scientific and practical peer-reviewed journal, 2023